otcStockExchange.com Initiates Coverage of Martin Nutraceuticals Inc.
Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals’ flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control.
Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days.
Other Active Stocks are Force Protection, Inc. (OTCBB: FRPT), Metropolis Technologies Corp. (Pink Sheets: MTPT), VaxGen (Pink Sheets: VXGN), Delta Air Lines Inc. (Pink Sheets: DALRQ), China Expert Technology, Inc. (OTCBB: CXTI), Terax Energy, Inc. (OTCBB: TERX), Nano-Proprietary, Inc. (OTCBB: NNPP).
To subscribe or get more information, visit our home page located at http://www.otcstockexchange.com .
We offer many investor relations programs to public companies. To feature a company on our web site or in our daily Newsletter or Mid-Day Stock Alert, please contact Chris Wheeler at 585-330-8514 , or via email at firstname.lastname@example.org .
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $20000.00 for the publication and circulation of this report and other IR services. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.
- Contact Information
- Christopher Wheeler
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.